抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展

 程序性死亡蛋白-1(programmed death protein-1, PD-1)和程序性死亡配体-1(programmed death-ligand 1, PD-L1)是一对免疫共抑制分子。以PD-1/PD-L1为靶点的药物重新激活了机体自身的抗肿瘤免疫并且在多种肿瘤中取得了良好而持久的疗效。然而，如何预测患者是否对治疗敏感及如何联合其他治疗提高抗PD-1/PD-L1治疗的反应率目前尚无定论。本文主要综述了PD-1/PD-L1通路的作用机制、抗PD-1/PD-L1治疗的研究进展，并探讨了预测抗PD-1/PD-L1疗效的生物标记物及联合免疫治疗的进展。

Research advancements of the anti-PD-1/PD-L1 therapy in oncotherapy

Programmed death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) are a pair of immune co-inhibitory molecules. Agents targeting the PD-1/PD-L1 pathway reactivated the autologous anti-tumor immune response and yielded strong and prolonged therapeutic effect in various cancer types. However, how to predict whether an individual is sensitive to the anti-PD-1/PD-L1 therapy and how to achieve higher response rates with combined therapies require further investigation. This review summarized the biological mechanism of the PD-1/PD-L1 pathway, the latest results of anti-PD-1/PD-L1 therapy, furthermore probed into potential biomarkers that predict the therapeutic effects and advancements in combined immune therapy.